The LANCET trial: a randomized clinical trial of Lantus for C-reactive protein reduction in early treatment of type 2 diabetes

Trial Profile

The LANCET trial: a randomized clinical trial of Lantus for C-reactive protein reduction in early treatment of type 2 diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2010

At a glance

  • Drugs Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms LANCET
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2009 Results published in JAMA: the Journal of the American Medical Association.
    • 03 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top